153624-46-5 Usage
Description
4-Isopropoxylphenylboronic acid is an organic compound with the chemical formula C9H13BO3. It is a white to off-white or light tan powder and is commonly used as a reactant in various chemical reactions and synthesis processes.
Uses
1. Used in Photodynamic Therapy:
4-Isopropoxylphenylboronic acid is used as a reactant for microwave-mediated click-chemistry synthesis of glyco-porphyrin derivatives with in vitro photo-cytotoxicity, which are applied in photodynamic therapy. This therapy is a treatment that involves the use of a photosensitizer drug, light, and oxygen to kill cancer cells.
2. Used in Palladium-Catalyzed Oxidative Cross-Coupling Reactions:
In this application, 4-Isopropoxylphenylboronic acid serves as a reactant in palladium-catalyzed oxidative cross-coupling reactions, which are essential for the formation of carbon-carbon bonds in organic synthesis.
3. Used in Ruthenium-Catalyzed Hydrogenation Reactions:
4-Isopropoxylphenylboronic acid is used as a reactant in ruthenium-catalyzed hydrogenation reactions, which involve the reduction of organic compounds using hydrogen gas in the presence of a ruthenium catalyst.
4. Used in Stereoselective Rhodium-Catalyzed Arylation:
4-Isopropoxylphenylboronic acid is used as a reactant in stereoselective rhodium-catalyzed arylation reactions, which are crucial for the formation of carbon-carbon bonds with specific stereochemistry in organic synthesis.
5. Used in Suzuki Reaction:
4-Isopropoxylphenylboronic acid is used in the Suzuki reaction, a type of cross-coupling reaction that involves the formation of carbon-carbon bonds using a palladium catalyst and a boronic acid or ester.
6. Used in the Synthesis of Potent Cytotoxic Analogues:
4-Isopropoxylphenylboronic acid is used to synthesize potent cytotoxic analogues of the marine alkaloid Lamellarin D, which have potential applications in cancer treatment.
7. Used in the Synthesis of COX-2 Inhibitors:
4-Isopropoxylphenylboronic acid is also used to synthesize cyclooxygenase-2 (COX-2) inhibitors, which are important in the development of anti-inflammatory and pain-relieving drugs.
Check Digit Verification of cas no
The CAS Registry Mumber 153624-46-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,5,3,6,2 and 4 respectively; the second part has 2 digits, 4 and 6 respectively.
Calculate Digit Verification of CAS Registry Number 153624-46:
(8*1)+(7*5)+(6*3)+(5*6)+(4*2)+(3*4)+(2*4)+(1*6)=125
125 % 10 = 5
So 153624-46-5 is a valid CAS Registry Number.
InChI:InChI=1/C9H13BO3/c1-7(2)13-9-5-3-8(4-6-9)10(11)12/h3-7,11-12H,1-2H3
153624-46-5Relevant articles and documents
Directed metalation?￡?cross-coupling strategies. Total syntheses of the alleged and the revised phenanthrene natural product gymnopusin
Wang, Xin,Fu, Jian-Min,Snieckus, Victor
, p. 2680 - 2694 (2013/03/13)
The total synthesis of gymnopusin (2) is described. The originally assigned structure for gymnopusin 1a was found to be incorrect by total synthesis using the Directed ortho-Metalation (DoM)?￡?Cross- Coupling?￡?Directed remote Metalation (DreM) sequence, a demonstrable key strategy for the regioselective construction of the 9-phenanthrol core. The revised structure of gymnopusin (2) was confirmed by synthesis by adopting the same strategy but involving a key remote anionic Fries-rearrangement step. Both routes highlight methodologies and concepts which may be of value in the regiocontrolled synthesis of phenanthrenoids specifically and in complex polycyclic aromatics in general. Copyright
Heterocyclic compounds
-
, (2008/06/13)
The invention concerns pharmaceutically useful compounds of the formula I, in which A1, A2, A3, A4, B1, m, Ar, W, X, Y, Z and R1 have any of the meanings defined herein, and their pharmaceutically acceptable salts, and pharmaceutical compositions containing them. The novel compounds possess endothelin receptor antagonist activity and are useful, for example, in the treatment of diseases or medical conditions in which elevated or abnormal levels of endothelin play a significant causative role. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.
